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Integration of pathway and protein-protein interaction (PPI) data can provide more information that could lead to new biologi-
cal insights. PPIs are usually represented by a simple binary model, whereas pathways are represented by more complicated 
models. We developed a series of rules for transforming protein interactions from pathway to binary model, and the protein in-
teractions from seven pathway databases, including PID, BioCarta, Reactome, NetPath, INOH, SPIKE and KEGG, were 
transformed based on these rules. These pathway-derived binary protein interactions were integrated with PPIs from other five 
PPI databases including HPRD, IntAct, BioGRID, MINT and DIP, to develop integrated dataset (named PathPPI). More de-
tailed interaction type and modification information on protein interactions can be preserved in PathPPI than other existing da-
tasets. Comparison analysis results indicate that most of the interaction overlaps values (OAB) among these pathway databases 
were less than 5%, and these databases must be used conjunctively. The PathPPI data was provided at http://proteomeview. 
hupo.org.cn/PathPPI/PathPPI.html. 
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It is increasingly clear that biological functions are mainly 
performed through diverse protein interactions. As such, 
studies on protein interactions have become important un-
dertakings over the last few years [14]. Protein interactions 
can be mainly obtained from two types of databases: path-
way and protein-protein interaction (PPI). Pathway data-
bases contain more diverse interactions, such as signalling, 
transcription regulation and metabolism, which generally 
present a clear in vivo interaction type and higher confi-
dence. By contrast, the PPIs from high throughput experi-
ments always feature vague in vivo information and lower 
confidence. 
Studies have shown that large, redundant and comple-
mentary information exists in pathway and PPI databases 
[5,6]. Integration of these pathways will result in more in-
formation that could lead to new biological insights [7]. For 
example, Ahn et al. [8], who explored the molecular mech-
anism and biomarker identification of prostate cancer by 
integrating diverse pathway and PPI databases, suggested 
that an integrated network could provide more detailed and 
interpretable roles of cancer-related genes in prostate cancer 
cells. Kirouac et al. [9] explored the inflammatory network 
structure by integrating the GeneGo, Cell MAP, PID and 
Reactome pathway databases and two other PPI databases. 
Several attempts have been made to develop databases that 
integrate pathway and PPI data, such as CPDB [10] and 
Pathway Commons [11] recently, while previous work fo-
580 Tang HL, et al.   Sci China Life Sci   June (2015) Vol.58 No.6 
cused only on PPI datasets [12,13]. 
Many challenges remain in terms of the integration of 
heterogeneous data from pathways and PPIs because such 
data are generally represented by different standards. PPIs 
are usually represented by a simple binary model, such as 
SIF (simple interaction format) and PSI MITAB [14] no 
matter how they were generally captured as n-ary (i.e., 
complex) or binary data, whereas pathways are represented 
by more complicated models, such as BioPAX [15], 
CellML [16] and SBML [17]. Although several models 
have been previously reported, the transformation method 
must be standardised to allow representation of integrated 
interactions to become more unified and convenient. In this 
study, we first build a binary model, and develop a series of 
rules to transform protein interaction from pathway to bina-
ry models. Some important information of interactions that 
were always neglected in earlier studies can be preserved in 
our binary model. Then, we integrate seven pathway and 
five PPI databases, and name this integrated dataset PathPPI, 
which can be obtained from http://proteomeview.hupo. 
org.cn/PathPPI/PathPPI.html. 
1  Materials and methods 
1.1  Pathway and PPI databases 
We mainly focused on pathway databases with the widely 
used BioPAX standard. In this study, six BioPAX-modelled 
pathway databases, including PID (contains only the data 
curated by PID, version 2012.03.17), BioCarta (from PID, 
version 2010.08.11), Reactome (version 2012.03.14) [18], 
NetPath (downloaded 2012.04.14) [19], INOH (version 
2011.01.31) [20] and SPIKE (version 2011.03.22) [21], 
were utilized. The non-metabolic pathway portion of KEGG 
(downloaded 2009.10.12) [22] was also included because of 
its large data size. The five integrated PPI databases in-
cluded HPRD (version R9) [23], IntAct (downloaded 
2013.10.22) [24], BioGRID (version 3.2.105) [25], MINT 
(version 2013.03.26) [26] and DIP (version 2013.07.07) 
[27]. Integrated databases contained STRING (version 9.1) 
[28], Pathway common (downloaded 2014.06.14) and 
CPDB (downloaded 2014.06.14). 
1.2  Categorisation of PathPPI 
The interaction type of PathPPIs must be depicted in a uni-
fied manner. Although PSI-MI provides molecular interac-
tion ontology for PPIs, it cannot fully depict PathPPIs, such 
as its structured way of indicating the outcome of an inter-
action. We developed a new categorisation based on Bi-
oPAX Level 3 standards and provided eight types of Path-
PPI interactions: BiochemicalReactionRegulation (BRR), 
TransportRegulation (TR), TransportWithBiochemicalRe-
actionRegulation (TBRR), ComplexAssemblyRegulation 
(CAR), ExpressionRegulation (ER), ComplexAssembly-
Interaction (CAI), GeneticInteraction (GI) and Molecular-
Interaction (MI) (Table 1). The meaning of each types can 
be obtained through the BioPAX standard [15] and the fol-
lowing transferring rules. Five regulation interactions, in-
cluding BRR, TR, TBRR, CAR and ER, contain an effect 
parameter that denotes regulation effects by Activation, 
Inhibition or Unspecified. BRR and TBRR also contain a 
modification parameter. A total of 22 common modifica-
tions with corresponding de-modifications were included in 
this work (Table S1 in Supporting Information). Several 
other rare modifications, such as cholesterol modification, 
will be added in further versions of our categorisation. 
The six PathPPI types, BRR, TR, TBRR, CAR, ER and 
CAI, are BiolPPIs depicted from a biological perspective 
and generally with clear in vivo mechanisms. In our catego-
risation, GI and MI are treated as TechPPIs since they are 
produced by certain PPI detection technologies and without 
clear in vivo information. 
1.3  Transformation of protein interactions from   
BioPAX into a binary model 
BioPAX (Biological Pathway Exchange, http://www.biopax. 
org/) is a standard language to represent biological path-
ways at the molecular and cellular level and to facilitate the 
exchange of pathway data by defining an open file format 
specification for the exchange of biological pathway data. 
BioPAX covers all major concepts familiar to biologists 
studying pathways, including metabolic and signaling 
pathways, gene regulatory networks and genetic and molec-  
Table 1  Categorisation of PathPPIsa) 
PathPPI Effect* Modification** Directionality 
BiolPPI 
BiochemicalReactionRegulation (BRR) ● ● Directed 
TransportRegulation (TR) ●  Directed 
TransportWithBiochemicalReactionRegulation (TBRR) ● ● Directed 
ComplexAssemblyRegulation (CAR) ●  Directed 
ExpressionRegulation (ER) ●  Directed 
ComplexAssemblyInteraction (CAI)   Undirected 
TechPPI 
GeneticInteraction (GI)   Undirected 
MolecularInteraction (MI)   Undirected 
a) *, With three status: Activation, Inhibition and Unspecified. **, With 22 pairs of modification currently (Table S1 in Supporting Information). 
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ular interactions. The BioPAX language uses a discrete 
representation of biological pathways. Dynamic and quanti-
tative aspects of biological processes, including temporal 
aspects of feedback loops and calcium waves, are not sup-
ported. BioPAX Level 3 defines five types of molecular 
interactions: Control, Conversion, GeneticInteraction, Mo-
lecularInteraction and TemplateReaction (Figure 1A). 
Conversion represents reactions in which one or more 
entities are physically transformed into other entities. The 
entities of Conversion can be protein, complex, DNA, RNA 
or small molecule, and we only focused on protein or com-
plex. Conversion has five subclasses: BiochemicalReaction, 
Transport, TransportWithBiochemicalReaction, Degrada-
tion and ComplexAssembly. The input and output entities 
of BiochemicalReaction, Transport and TransportWithBio-
chemicalReaction are always the same proteins but with 
different modification or subcellular status. Degradation 
generally has no protein product. Thus, we discarded these 
four types of interaction and dealt only with ComplexAs-
sembly. Each input entity was defined to have a CAI with 
each output entity in the binary model (Figure 1B). Given 
that ComplexAssembly representations are always reversi-
ble, the transformed CAI was non-directional. Thus, A has a 
CAI interaction with B, suggesting that A can produce B 
through non-covalent interactions with other molecules or 
through the decomposition of A and vice versa. 
Control contains three subclasses: Catalysis, Modulation 
and TemplateReactionRegulation. Modulation describes an 
interaction in which a small molecule alters the ability of an 
enzyme to catalyze a specific reaction. Thus, Modulation 
was discarded because our focus was protein interactions. 
Catalysis is a type of interaction in which a physical entity 
(a catalyst) accelerates a Conversion interaction by lowering 
its activation energy. For Catalysis, we defined the control-
ler have interactions with each output entity of the catalyzed 
Conversion interaction. The transformed PathPPI type de-
pends on the Conversion interaction type. For example, if 
the Conversion interaction is BiochemicalReaction in Bi-
oPAX, the transformed type will be BiochemicalReaction-
Regulation in PathPPI (Figure 1C). Effect and modification  
 
 
Figure 1  Illustration of the transformation from BioPAX to PathPPI model. A, BioPAX Level 3 contains five types of molecular interactions. Control and 
Conversion have subclasses. B, For ComplexAssembly, we specified that each input entity has a CAI with each output entity in the PathPPI model. C, For 
Control, we defined five types of interactions between the controller and products of controlled interaction for each controlled Conversion interaction. For 
example, if the controlled interaction is BiochemicalReaction, the controller has a BiochemicalReactionRegulation interaction with each product. Effect 
parameters can be obtained from controlType. D, Modification parameters can be obtained by comparing the modification state of the entity before and after 
reaction. E and F, Complex model allows PathPPI entities to be complexes or families, in contrast to a single model where each protein from one entity in 
the complex model interacts with each protein from another entity. 
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parameters can be obtained from the controlType and inter-
actionType items of Catalysis, respectively. All six pathway 
databases provide controlType but only NetPath and INOH 
provide interactionType (Table S2 in Supporting Infor-
mation). Other than the interactionType approach, we ob-
tained modification information from the changes of protein 
modification states during BiochemicalReaction in PID and 
Reactome. For example, if a protein is initially without 
modification but with phosphorylation after Biochemi-
calReaction, then we assigned the modification parameter 
Phosphorylation. For simplicity, in current version we only 
extracted modification information for the BiochemicalRe-
action interactions, in which there is only one input entity 
and its corresponding modification state is output or vice 
versa (Figure 1D). The modification information of the Bi-
ochemicalReaction interactions that contain multiple enti-
ties were not extracted. Modifications in PID and Reactome 
were identified by MOD ID [29]. We developed mapping 
relationships between MOD IDs and PathPPI modification 
parameters (Table S2 in Supporting Information). BioCarta 
and SPIKE do not provide modification information. The 
rules for the Catalysis with other types of Conversion sub-
classes were similar to that with BiochemicalReaction. 
TemplateReactionRegulation depicts an interaction in 
which the controller regulates a TemplateReaction (gene 
expression) interaction in the BioPAX model. The control-
ler (transcription factor) was defined to have an ER interac-
tion with the products (target genes) of gene expression. 
GeneticInteraction and MolecularInteraction are repre-
sented in binary form in BioPAX; thus, they were reserved 
in PathPPI categorisation. Although no GI was extracted 
from any of the six databases, we reserved GI in the Path-
PPI frame for further upgrades. TemplateReaction was ig-
nored because its input and output are always the same. 
Considering that we focused only on the protein interactions, 
we discarded the interactions containing interactor of small 
molecule, non-coding DNA or RNA. If a complex con-
tained small molecules, the proteins were preserved while 
small molecules were ignored. 
1.4  Transforming protein interactions from KGML 
into a binary model 
Given that KGML (KEGG Markup Language) adopts a 
binary-pair model, we can map KGML to PathPPI catego-
ries through lexical transformation. KGML categorisation is 
a two-level hierarchical structure containing four top-level 
categories: ECrel, PCrel, GErel and PPrel. ECrel depicts an 
enzyme-enzyme relation that two enzymes catalysing suc-
cessive reaction steps. PCrel depicts protein-compound in-
teractions. These two types of interaction were discarded. 
GErel represents the relation of transcription factor and tar-
get gene product. GErel has four interaction sub-types: re-
pression, expression, indirect effect and missing interaction. 
The missing interaction depicts missing interactions in mu-
tation, and it was ignored. The three remaining subtypes 
have corresponding types in PathPPI. PPrel is the most 
complicated category in KGML and its subtypes can be 
classified into three groups. The effect group contains two 
subtypes, activation and inhibition. The biological event 
group contains compound, phosphorylation, dephosphoryla-
tion, methylation, demethylation, glycosylation, ubiquitina-
tion, binding/association and dissociation. Three other sub-
types, including state change, missing interaction and indi-
rect effect, were classified as a third group. We developed a 
mapping relationship between PathPPI categories and all 
PPrel subtypes except for compound, dissociation, state 
change and missing interaction. We can obtain PathPPI ef-
fects and modification parameters based on the effect and 
biological event groups, respectively. For example, the in-
teractions of FYN and MAP4K2 are annotated with activa-
tion and phosphorylation in KGML, and we assigned the 
effect and modification parameters of this interaction Acti-
vation and Phosphorylation in PathPPI model. More map-
ping relationships are shown in Table S3 in Supporting In-
formation. 
1.5  Complex and single models of PathPPIs 
The entities (nodes) of interaction in current pathway data-
bases can be complex or family (that is, the node represents 
multiples proteins), or their more sophisticated combina-
tions, differing from traditional PPIs where the entities are 
only proteins. Thus, two types of model were proposed in 
PathPPI to represent binary interactions with complex or 
family entities (Figure 1E and F): the complex model, 
which allows the entities of PathPPIs to be complexes or 
families, and the single model, which assumes that all the 
proteins in a complex or family participate in interactions. 
For example, if a complex with three proteins interacts with 
another complex with two proteins in the complex model, 
the corresponding single model will represent 3×2=6 inter-
actions. The complex model is more accurate in depicting 
real protein interactions, whereas the single model is more 
convenient for network analysis. 
1.6  Unification of the protein identifier  
Different databases sometimes use different naming systems 
for gene names. KEGG (human) has its object identifiers 
(hsa). HPRD uses official gene symbol. BioGRID and 
SPIKE use gene ID, while the remaining databases (PID, 
BioCarta, Reactome, NetPath, INOH, IntAct, MINT and 
DIP) all adopt UniProt AC. For the purpose of reducing 
redundancy in gene level, we transformed all other hetero-
geneous IDs to gene symbol utilizing their built-in id map-
ping systems. 
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1.7  Confidence scores of PathPPI 
An existing method, Intscore (http://intscore.molgen. 
mpg.de/), was used to assign a confidence score for each 
pairs. IntScore is a web server for confidence scoring of 
biological interactions. It provides six methods for confi-
dence scoring, as well as the possibility to integrate the 
method-specific scores. We submitted all PathPPI (single 
model) to Intscore (default parameter) and obtained their 
integrated scores for each pairs.  
2  Results 
Seven pathway databases were transformed to extract a 
large number of binary interactions. We combined these 
pathway-derived binary interactions with traditional PPIs 
from five other PPI databases into PathPPIs. After the 
transformation of the seven pathway databases, we obtained 
seven binary interactions data sets, the proteins of which are 
identified by gene symbols or gene names if there are no 
corresponding gene symbols. PID, BioCarta, Reactome and 
INOH only contained biological PPIs (BiolPPIs), whereas 
KEGG, NetPath and SPIKE contained technical PPIs 
(TechPPIs) (for depiction of BiolPPI and TechPPI see the 
section of “Categorisation of PathPPI”). In addition, we 
obtained 169,203 non-redundant TechPPIs from the five 
other PPI databases (HPRD, IntAct, BioGRID, MINT and 
DIP). Finally, PathPPI integrated 22,737 BiolPPIs and 
174,770 TechPPIs in the complex model, and involved 
16,768 human genes. The BiolPPI part contained 10,627 
BRRs, 239 TRs, 132 TBRRs, 948 CARs, 3,938 ERs and 
6,853 CAIs (Table 2). 
2.1  Protein and interaction scales in BiolPPI datasets 
First, we searched for the total number of unique proteins 
represented in the BiolPPI datasets. Results showed that 
SPIKE contains the highest number of proteins, reaching as 
high as 3,578. PID, Reactome and KEGG, which have simi- 
Table 2  BiolPPI composition of the seven BiolPPI datasets (Complex 
model)a) 
Dataset BRR TR TBRR CAR ER CAI 
PID 2,160 200 131 709 1,700 5,195 
BioCarta 1,149 46 1 256 242 1,143 
Reactome 1,519 0 0 0 237 0 
NetPath 582 0 0 0 0 0 
INOH 198 2 0 1 0 691 
KEGG 1,823 0 0 0 284 0 
SPIKE 4,504 0 0 0 1,776 0 
BiolPPI 10,627 239 132 948 3,938 6,853 
a) It was noted that Reactome and NetPath treat the ComplexAssembly 
as BiochemicalReaction and SPIKE does not provide ComplexAssembly in 
its BioPAX file. 
lar scales, contained 2,666, 2,580 and 2,489 proteins, re-
spectively. BioCarta, INOH and NetPath contained 1,436, 
843 and 385 proteins, respectively. The total number of 
BiolPPI proteins was 7,012, covering 1/3 of all human pro-
tein-coding genes. For entities that can be considered family 
or complex in the complex model, we examined the propor-
tion of complexes and families occupying whole entities in 
each dataset. Results showed that there are high complex 
proportions in INOH (56.44%), PID (51.73%), Reactome 
(45.77%) and BioCarta (40.54%), as well as high protein 
family proportions in INOH (41.33%), KEGG (32.65%) and 
Reactome (28.80%) (Table S4 in Supporting Information). 
SPIKE contributed the most BRRs (4,504) and ERs 
(1,776) to PathPPI (complex model). PID contributed the 
highest number of other BiolPPI types, the second most 
BRR (2,160), and ERs (1,700) (Table 2). Reactome, 
NetPath and SPIKE did not have CAI and CAR interactions 
because Reactome and NetPath treat the ComplexAssembly 
as BiochemicalReaction and SPIKE does not provide Com-
plexAssembly in its BioPAX file, suggesting that there ex-
ists a large difference in the usage of BioPAX standards. 
NetPath and INOH did not have ER interactions. These dif-
ferences show that different pathway databases build path-
ways with different details. The number of interactions ex-
panded sharply with the single model, especially in Reac-
tome and INOH, because of their high complex and family 
proportions (Table S5 in Supporting Information). 
The proportions of the effect parameter Activation are 
higher than those of Inhibition in all datasets but these pro-
portions were variant. The Activation:Inhibition ratio was 
approximately 20:1 in PID but less than 2:1 in SPIKE (Ta-
ble S6 in Supporting Information). Interestingly, many 
BRRs existed with conflicting annotations in KEGG and 
SPIKE. For example, the AKT family (AKT1, AKT2 and 
AKT3) have both activation and inhibition interactions with 
CHUK, IKBKB and IKBKG. About 85% of the modifica-
tion parameters were Phosphorylation, followed by 
Dephosphorylation (~7%), Ubiquitination (~6%) and Acet-
ylation (~1%). No modification information was obtained 
from SPIKE, BioCarta and Reactome (Table S6 in Sup-
porting Information). 
2.2  Overlaps among the BiolPPI datasets 
We used the index OAB to measure the overlap of sets A and 
B, which is equal to the arithmetic average of the ratios of 
the element numbers of (A∩B) divided by sets A and B, 
respectively [30]. The protein OAB values of each two Bi-
olPPI data sets ranged from 35.74% to 51.29% among the 
seven pathway datasets, whereas most of the interaction 
OAB values were less than 5.00% in the complex model 
(Table 3) and also low in the single model (Table S7 in 
Supporting Information). These findings indicate that high 
protein overlaps exist in these datasets but the interaction 
overlaps are unexpectedly low, considering their common 
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origin of being curated from the literature. This suggests 
that the coverage of each pathway database is far from 
complete. 
2.3  Overlaps between TechPPIs and BiolPPIs 
TechPPIs were mainly from high throughput technologies 
with high false positive rates, while BiolPPIs were generally 
produced by molecular biological experiments and could be 
served as real in vivo interactions. Here, we calculated the 
overlaps of different types of BiolPPIs and TechPPIs, which 
can represent the real in vivo interaction-detecting capabili-
ties of the high-throughput technologies in some way. We 
also defined sensitivity to measure the detecting capability 
of the detection technology, which is equal to the ratio of 
the element number of (BiolPPI∩TechPPI) divided by Bi-
olPPI group. 
BiolPPIs were classified based on their interaction types. 
TechPPIs annotated with ‘two hybrid’ (Y2H), ‘anti bait 
co-immunoprecipitation’ (ABCoIP) and ‘affinity technolo-
gy’ (AffTech) were selected as three technology groups. In 
addition, interactions with ‘in vivo’ annotation from HPRD 
that were mainly detected by small-scale experiments were 
treated as a control technology group. 
Results showed that only a small part of the TechPPIs 
overlapped with BiolPPIs (Table 4), suggesting that the 
biological functions of most TechPPIs remain unclear, or 
the high-throughput experiments have surprisingly high 
false positive rate. In addition, all of the sensitivity values of 
three technology groups were very low. 
2.4  Top degree hub proteins in BiolPPI 
In the signalling network (BRR) of BiolPPI, ATM had the 
highest out-degree (number of directed downstream entities), 
reaching as high as 849, far more than any other entity. 
RHOA and RAC1 had the highest in-degree (number of 
directed upstream entities). In the transcription regulation 
network (ER) of BiolPPI, TP53 had the highest out-degree 
(174), whereas KLK3 had the highest in-degree (77). TP53 
also has the 3rd highest of in-degree in signalling network, 
indicating it is a vital transcription factor of jointing the end 
of signalling cascade and the target genes (Table S8 in 
Supporting Information). The top-degree proteins in TR, 
TBRR, CAR and CAI networks were shown in Tables 
S9S12.  
We also examined the contributions of these degrees 
from the original seven pathway databases. Many of these  


















PID: 2666  335 (7.70%) 59 (1.99%) 77 (7.02%) 75(4.58%) 126 (3.44%) 390 (5.13%) PID: 9,898 
BioCarta: 1436 879(47.09%)  23 (1.07%) 52 (5.41%) 40(2.96%) 82 (3.29%) 165 (4.30%) BioCarta: 2,790
Reactome: 2580 988(37.68%) 677 (36.69%)  9 (1.03%) 10(0.85%) 45 (2.29%) 52 (1.92%) Reactome: 1,739
NetPath: 385 325 (48.30%) 217 (35.74%) 254 (37.91%)  26 (3.69%) 40 (4.33%) 349 (32.87%) NetPath: 581 
INOH: 843 619 (48.32%) 418 (39.35%) 459 (36.12%) 210 (39.73%)  47 (3.68%) 52 (3.34%) INOH: 892 
KEGG: 2489 1,194 (46.38%) 730 (40.08%) 993 (39.19%) 283 (42.44%) 646 (51.29%)  383 (11.62%) KEGG: 2,249 


















a) Different types of interaction linking two identical entities were counted only once. OAB values are in brackets. The upper right triangle part depicts the 
overlaps of interactions and the lower left triangle part depicts the overlaps of proteins. 













BRR: 71,535 1130 (1.58%) 783 (1.09%) 3,754 (5.52%) 3,662 (5.12%) 8,070 (11.28%) 
TBRR: 358 23 (6.42%) 23 (6.42%) 55 (15.36%) 64 (17.88%) 110 (30.73%) 
TR: 784 30 (3.83%) 26 (3.32 %) 116 (14.80%) 76 (9.69%) 195 (24.87%) 
CAR: 4,375 130 (2.97%) 93 (2.13%) 462 (10.56%) 425 (9.71%) 838 (19.15%) 
ER: 7,158 118 (1.65%) 61 (0.85%) 291 (4.07%) 210 (2.93%) 528 (7.38%) 
CAI: 48,768 1,183 (2.43%) 667 (1.37%) 3,030 (6.21%) 2,674(5.48%) 5,820 (11.93%) 
BiolPPI: 125,348 2,019 (1.61%) 1,214 (0.97%) 5,964 (4.76%) 5,339(4.26%) 12,458 (9.94%) 
a) The sensitivity values, which equal to the ratios of the element number of (BiolPPI∩TechPPI) divided by BiolPPI group, are in brackets. AllPPI group 
contains the PPIs from five PPI databases. The BiolPPIs are depicted in single model. 
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high degree nodes (hubs) were cooperatively contributed 
from multiple sources other than a dominant one. Especially, 
out-degree of MAPK1 and in-degree of HRAS#KRAS# 
NRAS in BiolPPI signalling network were contributed no 
more than 50% from any original pathway database alone 
(Figure 2). The same situations occurred in in-degrees of 
CDKN1A, MYC, CDKN2A, BCL2 and IL8 in BiolPPI 
transcription regulation network (Figure 2; Table S13 in 
Supporting Information). The result suggested the necessary 
of dataset integration. 
2.5  Comparison with existing databases 
We compared our PathPPI categorisation and preserved 
information with those of Reactome, STRING, CPDB and 
Pathway Commons (Table 5). Reactome developed very 
simple rules of transforming the protein interaction from 
pathway to binary model and defined only four interaction 
types [18]. STRING and CPDB contained six and three in-
teraction types respectively, but both of them did not pro-
vide the rules publicly. Pathway Commons developed the 
most detailed rules and defined nine interaction types to 
cover as many relationships as possible, such as the 
CO_CONTROL interaction to depict the relationship of two 
entities that control the same reaction and SEQUENTIAL_ 
CATALYSIS for two entities catalyzing two neighbour 
reactions [11]. PathPPI covered fewer relationship types 
than Pathway Commons but preserves more information 
after model transformation, which is very valuable in net-
work analysis. For example, the effect and modification 
information reserved in PathPPI were missing in all three 
methods. Another advantage of our PathPPI is that a large 
amount of traditional PPIs are integrated as TechPPIs. 
These five datasets were further divided into subsets 
based on TechPPI, complex, signaling and transcription 
interaction (Table 5). PathPPI contained four interaction 
types. STRING and Pathway common contains three types, 
while Reactome and CPDB had two and one respectively 
(CPDB did not provide signalling, transcription and com-
plex interactions for downloading). CPDB had the most 
TechPPT, up to 468,598 (Figure S1 in Supporting Infor-
mation). Next were STRING and PathPPI. PathPPI had the 
most complex and signalling interactions. The interaction 
OAB values of each two interaction data sets ranged from  
 
 
Figure 2  Degrees of the seven nodes that from top 10 signalling or transcription regulation degree list, and are with no more 50% from any original path-
way database alone. 
Table 5  Comparison of PathPPI with four existing interaction categorisations 
Parameters PathPPI Reactome STRING Pathway commons CPDB 
Preserved 
information 
Directionality Yes Yes Yes Yes Yes 
Effect Activation/ 
Inhibition/Unspecified 
    
Modification 22 pairs of modification     
Interaction 
categorisation 
TechPPI GI, MI  binding INTERACTS_WITH Physical interaction 









Expression ER  expression  Gene regulation 





Transport TR, TBRR    
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0.29% to 94.75% among the 13 datasets (Table S14 in 
Supporting Information). The OAB values between Path-
PPI_PPI and STRING_PPI, PC_PPI were more than 
20.00%, but only 9.52% for CPDB_PPI. PathPPI_Cmp had 
higher OAB values with PC_Cmp than Reactome_Cmp. The 
lower OAB values between PathPPI_Sig and PC_Sig result-
ed mainly from their difference interaction transformation 
approaches from pathway to pairs model. Totally, the OAB 
values indicated that there existed a significant difference 
between PathPPI and other four databases.  
2.6  An example in disease genes identification 
Screening of genes resulting in specific diseases has long 
been one of the major tasks in human genetics studies. Re-
cently, numerous methods based on network, that can pro-
vide interpretability to a gene or protein, and gene-     
expression data have been proposed to screen potential dis-
ease genes [31,32]. Here, Liver cancer metastasis genes 
were screened based on PathPPI and two gene expression 
datasets (Ye’s [33] and Zhang’s data [34]) by Chuang’s 
method [35]. Ye’s data contained 7163 gene expression 
values for 36 primary metastasis and 26 non-metastasis 
samples by microarray technology. Zhang’s data provided 
the 7794 protein quantitative values for two non-metastasis 
and six metastasis cells by mass spectrum technology. Two 
datasets were normalized by median normalization method. 
Then, using Chuang’s method we screened 5, 1 the co-  
expression subnetworks (P<105) from BRR and ER inter-
action network respectively in Ye’s dataset (Table S15 in 
Supporting Information). and 5, 0 subnetworks (P<105) in 
Zhang dataset (Table S16 in Supporting Information). Fur- 
thermore, we found that three subnetwork containing at 
least two known metastasis-association genes (Figure 3). 
These three subnetworks can be paid more attention in fur- 
ther research.  
3  Discussion 
Integration of pathway and PPI data can provide more in-
formation that could lead to new biological insights. Con-
sidering that pathways and PPIs are generally represented 
by different standards, model transformations are inevitable. 
One solution to this problem is to transform pathway into 
binary models. In this study, we developed a series of rules 
to realise such transformations. Some important information 
of interactions that is always neglected in earlier studies, 
such as modification information, is preserved in PathPPI. 
A categorisation was established to depict pathway-  
derived binary interactions and traditional PPIs. Similar to 
the Reactome, STRING and Pathway Commons categorisa-
tions, PathPPI categorisation is also not fully systematic, but 
it is helpful to deal with current pathway data. A more sys-
tematic categorisation based on biological events is desired. 
In addition, a number of special relationships (e.g., CO_ 
CONTROL in Pathway Commons) in BioPAX that are not 
extracted in the current PathPPI version will be considered 
in our future work. 
Two fundamental problems exist in the transformation of 
interactions from the pathway model to the binary model. 
One is the lack of efficient transformability between the 
pathway and PPI models. BioPAX and PSI-MI are the 
mainstream standards of pathways and PPIs, respectively. 
Although BioPAX is designed to contain all PSI-MI func-
tions, it does not consider transformability with PSI-MI. 
Multiple data models will inevitably exist for respective 
advantages and suitable fields. Thus, the efficient trans- 
formability between BioPAX and PSI-MI should be im-
proved. Another problem is that some pathway databases do 
not provide enough information or show divergent use of 
standards. For example, Reactome and PID do not provide 
the conversionType items of BiochemicalReaction and Bio-  
 
 
Figure 3  Three co-expression modules with known cancer metastasis genes. Known cancer metastasis and down-regulated genes were marked by “*” and 
“” respectively. The color represented the –log of P values of each gene (rank-sum test). ADAM17, EGFR, HBEGF, IGF1R, MMP9, PLD2, and VEGFB in 
the second module were associated with cell migration (Gene Ontology).  
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Carta and SPIKE do not contain modification information in 
the BioPAX model. The divergent use of BioPAX may 
bring about errors or information loss. For example, the 
interaction, that a set of physical entities aggregated via 
non-covalent interactions, should be depicted by Complex-
Assembly, but it is BiochemicalReaction in Reactome. The 
latter should be used to depict covalent reactions. 
We propose a combination of the complex and single 
models to represent PathPPIs. The entity in complex models 
may be very complicated, for example, the entity 
GGT1*GGT1#GGT2*GGT2#GGT5*GGT5#GGT6*GGT6
#GGT7*GGT7 in Reactome, which represents a protein 
complex family (the marks * and # are used to separate the 
members of the complex and family, respectively). The 
complex model is more accurate in interaction description 
but inconvenient for analysis. The single model is conven-
ient for analysis but an inaccurate and cumbersome ap-
proach for depicting interactions. We thus recommend the 
complex model equipped with corresponding data extract-
ing methods. 
4  Conclusion 
This study aimed to provide a method to standardise the 
integration of pathway and PPI data. We obtained numerous 
BiolPPIs by transformation of seven pathway databases that 
are highly complementary with traditional PPIs. These Bi-
olPPIs were integrated with traditional PPIs (TechPPIs) into 
the PathPPI dataset, which can provide great knowledge 
with hierarchical information content and confidence. Alt-
hough PathPPI requires further improvement because of 
data source constraints, it is a starting point for the stand-
ardisation of pathway and PPI data integration. More com-
plete standardisation requires collaboration from communi-
ties around the world. 
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